APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

NCT03053466 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Microsatellite Instability
Mismatch Repair Deficiency
Cancer of Unknown Primary Site

Interventions

DRUG: APL-501

Sponsor

Apollomics (Australia) Pty. Ltd.

Collaborators

[object Object]
[object Object]